Drug Profile
BIIB 061
Alternative Names: BIIB-061Latest Information Update: 15 Jun 2023
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Biogen
- Class Neuroprotectants; Small molecules
- Mechanism of Action Myelin protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 15 Jun 2023 Discontinued - Phase-I for Multiple sclerosis (In volunteers) in USA (PO) (Biogen pipeline, June 2023)
- 01 Jun 2023 Biogen withdraws a phase II trial prior to enrolment in Multiple sclerosis (Adjunctive treatment) (PO), due to lack of stronger preclinical effects on remyelination(NCT04079088)
- 13 Dec 2021 BIIB 061 is still in phase I trials for Multiple-sclerosis in USA (Biogen website, December 2021)